Phibro Animal Health Co. (NASDAQ:PAHC - Free Report) - Research analysts at Zacks Research raised their Q3 2026 earnings estimates for shares of Phibro Animal Health in a note issued to investors on Tuesday, December 10th. Zacks Research analyst R. Department now anticipates that the company will earn $0.35 per share for the quarter, up from their prior estimate of $0.33. The consensus estimate for Phibro Animal Health's current full-year earnings is $1.62 per share.
A number of other research firms also recently commented on PAHC. JPMorgan Chase & Co. initiated coverage on Phibro Animal Health in a research note on Tuesday, September 10th. They issued a "neutral" rating and a $22.00 price objective on the stock. StockNews.com lowered Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a report on Friday, December 6th. Barclays upped their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an "underweight" rating in a report on Tuesday, November 12th. Finally, Bank of America lifted their price objective on shares of Phibro Animal Health from $13.00 to $15.00 and gave the stock an "underperform" rating in a research note on Friday, August 30th.
Read Our Latest Stock Analysis on Phibro Animal Health
NASDAQ PAHC opened at $23.88 on Friday. The firm has a market capitalization of $967.14 million, a PE ratio of 55.54, a P/E/G ratio of 0.62 and a beta of 0.51. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69. Phibro Animal Health has a 12 month low of $10.03 and a 12 month high of $25.98. The company's 50 day simple moving average is $23.58 and its 200 day simple moving average is $20.52.
Several large investors have recently added to or reduced their stakes in PAHC. Sofinnova Investments Inc. purchased a new position in shares of Phibro Animal Health during the second quarter valued at $3,975,000. Acadian Asset Management LLC grew its stake in Phibro Animal Health by 6.3% during the 2nd quarter. Acadian Asset Management LLC now owns 717,506 shares of the company's stock valued at $12,027,000 after acquiring an additional 42,299 shares in the last quarter. Algert Global LLC increased its holdings in shares of Phibro Animal Health by 521.1% in the 3rd quarter. Algert Global LLC now owns 71,335 shares of the company's stock valued at $1,606,000 after purchasing an additional 59,850 shares during the period. nVerses Capital LLC purchased a new stake in shares of Phibro Animal Health in the third quarter worth approximately $70,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Phibro Animal Health by 5.7% in the second quarter. Dimensional Fund Advisors LP now owns 775,470 shares of the company's stock worth $13,005,000 after purchasing an additional 42,086 shares in the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 18th. Stockholders of record on Wednesday, November 27th will be given a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 2.01%. The ex-dividend date is Wednesday, November 27th. Phibro Animal Health's dividend payout ratio (DPR) is currently 111.63%.
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Phibro Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.
While Phibro Animal Health currently has a "Sell" rating among analysts, top-rated analysts believe these five stocks are better buys.